TRIMIPRAMINE MALEATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trimipramine Maleate, and when can generic versions of Trimipramine Maleate launch?
Trimipramine Maleate is a drug marketed by Breckenridge, Elite Labs Inc, and Usl Pharma. and is included in five NDAs.
The generic ingredient in TRIMIPRAMINE MALEATE is trimipramine maleate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the trimipramine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trimipramine Maleate
A generic version of TRIMIPRAMINE MALEATE was approved as trimipramine maleate by ELITE LABS INC on August 2nd, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRIMIPRAMINE MALEATE?
- What are the global sales for TRIMIPRAMINE MALEATE?
- What is Average Wholesale Price for TRIMIPRAMINE MALEATE?
Summary for TRIMIPRAMINE MALEATE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Patent Applications: | 654 |
Drug Prices: | Drug price information for TRIMIPRAMINE MALEATE |
DailyMed Link: | TRIMIPRAMINE MALEATE at DailyMed |
Pharmacology for TRIMIPRAMINE MALEATE
Drug Class | Tricyclic Antidepressant |